证券代码：300981 证券简称：中红医疗 公告编号：2025-092 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 变更注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《医疗器械变更注册 （备案）文件》。具体变更情况如下： 董事会 二〇二五年十月十五日 | 产品名称 | 注册证编号 | 注册分类 | 变更内容 | 备注 | | --- | --- | --- | --- | --- | | 一次性使用输 | 国械注准 | | | 本文件与"国械注准 | | | | Ⅲ类 | 型号规格、技术要求变更。 | 20163141379"注册证 | | 液器 带针 | 20163141379 | | | | | | | | | 共同使用。 | 二、对公司的影响及风险提示 上述医疗器械注册证的变更是在原有注册证的基础上根据相关标准进行的 相应变更。一次性使用输液器（带针）领域相关产品的实际销售情况取决于未来 ...

Core Viewpoint - 中红医疗 is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model to produce for overseas brand owners [2][4]. Group 1: Company Overview - 中红医疗 was established on December 22, 2010, and listed on April 27, 2021, focusing on the research, production, and sales of high-quality disposable protective gloves [9]. - The company's main revenue sources are health protection products (89.48%), safety infusion products (6.22%), and innovative incubation products (4.30%) [9]. - As of June 30, 2025, 中红医疗 reported a revenue of 1.238 billion yuan, a year-on-year increase of 7.76%, while net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. Group 2: Market Position and Performance - The company benefits from a high overseas revenue ratio of 81.56%, aided by the depreciation of the RMB [4]. - 中红医疗 is classified as a state-owned enterprise, with the ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The stock has a current market capitalization of 5.695 billion yuan, with a trading volume of 59.614 million yuan and a turnover rate of 1.16% [1]. Group 3: Product Innovation and Development - 中红医疗 emphasizes innovation through the integration of digital technology in product development, aiming to provide high-quality, innovative medical consumables and equipment [3]. - The company showcased its products at the 12th Beijing Pet Expo, highlighting the UniFusion SP50 Vet and UniFusion VP50 Vet veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture [2]. Group 4: Shareholder and Financial Analysis - As of June 30, 2025, 中红医疗 had 20,200 shareholders, with an increase of 0.40% from the previous period, and an average of 19,502 circulating shares per person, up by 9.52% [10]. - The average trading cost of the stock is 14.58 yuan, with recent buying activity indicating weak accumulation [8].

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Business Overview - Zhonghong Medical's main business includes the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves, with health protection products accounting for 89.48% of revenue [9]. - The company has a significant international presence, with 81.56% of its revenue coming from overseas markets, benefiting from the depreciation of the RMB [4]. - The company is state-owned, with the ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. Group 2: Product Innovation and Market Presence - Zhonghong Medical showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical needs [2]. - The company emphasizes innovation through digital technology, aiming to develop high-quality, innovative medical consumables and equipment, positioning itself as a leading provider of intelligent medical solutions [3]. Group 3: Financial Performance - For the first half of 2025, Zhonghong Medical reported a revenue of 1.238 billion yuan, representing a year-on-year growth of 7.76%, while the net profit attributable to shareholders decreased by 82.35% to 5.7429 million yuan [10]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11].

Core Viewpoint - The announcement indicates that the company’s subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd., is participating in a centralized procurement project for disposable pressure extension tubes and syringes in Fujian Province, which may lead to selected products for procurement [1] Group 1 - The company’s subsidiary, Kelong Medical, is involved in a bidding process for a centralized procurement project in Zhangzhou, Fujian Province [1] - The procurement project includes disposable pressure extension tubes and syringes, indicating a focus on essential medical supplies [1] - The announcement suggests potential for increased sales and market presence if selected in the procurement process [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), recently participated in a bidding process for a centralized procurement project for disposable pressure extension tubes and syringes in Zhangzhou, Fujian Province [1] Summary by Category - **Company Participation** - Kelong Medical is involved in the bidding for a centralized procurement project in Fujian Province [1] - **Product Selection** - Some products from Kelong Medical are expected to be selected for the aforementioned centralized procurement project [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), recently participated in a centralized procurement project for disposable pressure extension tubes and syringes in Fujian Province, Zhangzhou City, indicating potential selection of some products for this procurement project [1] Group 1 - Kelong Medical is involved in a centralized procurement project for medical devices in Fujian Province [1] - The procurement project includes disposable pressure extension tubes and syringes [1] - The announcement suggests that Kelong Medical's products are likely to be selected for the procurement project [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), participated in a bidding process for a centralized procurement project for disposable pressure extension tubes and syringes in Fujian Province, Zhangzhou City, indicating potential for increased market share and brand influence [1] Group 1: Company Performance - Kelong Medical's projected sales revenue from syringes for the year 2024 is 64.13 million yuan, accounting for 34.84% of Kelong Medical's total revenue and 2.61% of Zhonghong Medical's total revenue for the same year [1] - The selected products will be prioritized for use in medical institutions within the procurement region, ensuring the fulfillment of agreed procurement volumes, which is expected to positively impact the company's long-term development [1] Group 2: Market Impact - The successful selection of Kelong Medical's products in the procurement project is anticipated to enhance market sales, increase market share, and improve brand influence [1]

Core Viewpoint - Zhonghong Medical (300981.SZ) announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd. (referred to as "Kelong Medical"), participated in a bidding project for centralized procurement of disposable pressure extension tubes and syringes in Fujian Province, Zhangzhou City, indicating potential selection for the procurement project [1] Group 1: Company Developments - Kelong Medical's syringe sales revenue for 2024 is projected to be 64.13 million yuan, accounting for 34.84% of Kelong Medical's total revenue and 2.61% of the company's overall revenue for the same year [1] - The selected products will be prioritized for use in medical institutions within the procurement region, ensuring the completion of the agreed procurement volume, which is expected to enhance market sales and brand influence [1] Group 2: Market Impact - The successful procurement and subsequent signing of sales contracts are anticipated to positively impact the long-term development of the company by increasing market share and brand recognition [1]

证券代码：300981 证券简称：中红医疗 公告编号：2025-091 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 科伦医械注射器 2024 年度销售收入为 6413 万元，占科伦医械 2024 年度营 业收入的 34.84%，占公司 2024 年度营业收入的 2.61%。 中红普林医疗用品股份有限公司 董事会 科伦医械上述拟中选产品的采购周期内，采购地区的医疗机构将优先使用公 司拟中选产品，并确保完成约定采购量，后续签订购销合同并实施后，将有利于 进一步扩大中选产品的市场销售，提高市场占有率，提升品牌影响力，对公司长 远发展产生积极影响。 三、风险提示 本次拟中选产品相关采购合同尚未签订，后续事项及对公司的影响程度具有 不确定性。公司将密切关注该事项的进展情况并及时履行信息披露义务，敬请广 大投资者谨慎决策，注意投资风险。 特此公告 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加福建省漳州市一次 性使用压力 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-089 中红普林医疗用品股份有限公司 关于子公司江西科伦医疗器械制造有限公司完成医疗器械 延续注册的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）子公司江西科伦医疗 器械制造有限公司于近期取得国家药品监督管理局颁发的《中华人民共和国医疗 器械注册证》，上述注册证为原有产品的延续注册，有效期限由原 2025 年 9 月 28 日到期延续至 2030 年 9 月 28 日到期。上述注册证具体情况如下： 一、基本信息 | 注册人名称 | 产品名称 | | 注册证编号 | 注册分类 | | 注册证有效期 | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 江西科伦医 疗器械制造 | 一次性使用流 量设定微调式 | | 国械注准 | Ⅲ类 | 2025 年 | 9 月 | 29 日至 | 适 用 于 静 脉 重 力 | | | | | 20153142343 | | ...